We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Original Investigation |

Nonmyeloablative HLA-Matched Sibling Allogeneic Hematopoietic Stem Cell Transplantation for Severe Sickle Cell Phenotype

Matthew M. Hsieh, MD1,2; Courtney D. Fitzhugh, MD1,2; R. Patrick Weitzel, PhD1,2; Mary E. Link, BSN1,2; Wynona A. Coles, MPH1,2; Xiongce Zhao, PhD3; Griffin P. Rodgers, MD1,2; Jonathan D. Powell, MD4; John F. Tisdale, MD1,2
[+] Author Affiliations
1Molecular and Clinical Hematology Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland
2National Heart, Lung, and Blood Institute, Bethesda, Maryland
3Office of Clinical Director, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland
4Sidney Kimmel Cancer Center, Johns Hopkins Medical Institute, Baltimore, Maryland
JAMA. 2014;312(1):48-56. doi:10.1001/jama.2014.7192.
Text Size: A A A
Published online

Importance  Myeloablative allogeneic hematopoietic stem cell transplantation (HSCT) is curative for children with severe sickle cell disease, but toxicity may be prohibitive for adults. Nonmyeloablative transplantation has been attempted with degrees of preparative regimen intensity, but graft rejection and graft-vs-host disease remain significant.

Objective  To determine the efficacy, safety, and outcome on end-organ function with this low-intensity regimen for sickle cell phenotype with or without thalassemia.

Design, Setting, and Participants  From July 16, 2004, to October 25, 2013, 30 patients aged 16-65 years with severe disease enrolled in this nonmyeloablative transplant study, consisting of alemtuzumab (1 mg/kg in divided doses), total-body irradiation (300 cGy), sirolimus, and infusion of unmanipulated filgrastim mobilized peripheral blood stem cells (5.5-31.7 × 106 cells/kg) from human leukocyte antigen–matched siblings.

Main Outcomes and Measures  The primary end point was treatment success at 1 year after the transplant, defined as a full donor-type hemoglobin for patients with sickle cell disease and transfusion independence for patients with thalassemia. The secondary end points were the level of donor leukocyte chimerism; incidence of acute and chronic graft-vs-host disease; and sickle cell–thalassemia disease-free survival, immunologic recovery, and changes in organ function, assessed by annual brain imaging, pulmonary function, echocardiographic image, and laboratory testing.

Results  Twenty-nine patients survived a median 3.4 years (range, 1-8.6), with no nonrelapse mortality. One patient died from intracranial bleeding after relapse. As of October 25, 2013, 26 patients (87%) had long-term stable donor engraftment without acute or chronic graft-vs-host disease. The mean donor T-cell level was 48% (95% CI, 34%-62%); the myeloid chimerism levels, 86% (95% CI, 70%-100%). Fifteen engrafted patients discontinued immunosuppression medication with continued stable donor chimerism and no graft-vs-host disease. The normalized hemoglobin and resolution of hemolysis among engrafted patients were accompanied by stabilization in brain imaging, a reduction of echocardiographic estimates of pulmonary pressure, and allowed for phlebotomy to reduce hepatic iron. The mean annual hospitalization rate was 3.23 (95% CI, 1.83-4.63) the year before, 0.63 (95% CI, 0.26-1.01) the first year after, 0.19 (95% CI, 0-0.45) the second year after, and 0.11 (95% CI, 0.04-0.19) the third year after transplant. For patients taking long-term narcotics, the mean use per week was 639 mg (95% CI, 220-1058) of intravenous morphine–equivalent dose the week of their transplants and 140 mg (95% CI, 56-225) 6 months after transplant. There were 38 serious adverse events: pain and related management, infections, abdominal events, and sirolimus related toxic effects.

Conclusions and Relevance  Among 30 patients with sickle cell phenotype with or without thalassemia who underwent nonmyeloablative allogeneic HSCT, the rate of stable mixed-donor chimerism was high and allowed for complete replacement with circulating donor red blood cells among engrafted participants. Further accrual and follow-up are required to assess longer-term clinical outcomes, adverse events, and transplant tolerance.

Trial Registration  clinicaltrials.gov Identifier: NCT00061568

Figures in this Article

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview


Place holder to copy figure label and caption
Figure 1.
Donor Leukocyte Engraftment After Hematopoietic Stem Cell Transplantation (HSCT)

Eleven patients who were still receiving immunosuppression medication (sirolimus) are shown in panels A (myeloid) and C (lymphoid). Fifteen patients who later discontinued immunosuppression medication are shown in panels B and D. The orange lines and data points represent values after patients ceased immunosuppression medication. At the very early time points, eg, 1 month after transplant when patients began to shows signs of white blood cell engraftment, there often were not sufficient numbers of leukocytes for chimerism analysis. Thus not all time points include all 26 data points. At later time point, some patients could not travel back at the half-year marks (eg, 2.5, 3.5, or 4.5 year) for chimerism analysis; thus, there are fewer data points at those times.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.
Subsets of T-Lymphocytes Recovery After Hematopoietic Stem Cell Transplantation Among Engrafted Patients

Each data point represents data value for that patient at that time point. The black bars represent the means.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 3.
Hospitalization Rate and Narcotics Use

A, Median hospital admission rate per patient a year before, 1 year after, 2 years after HSCT, and 3 years after Hematopoietic Stem Cell transplantation (HSCT) and later per year. B, Among 11 participants who took narcotics long-term, median intravenous morphine equivalent doses of narcotics per week are shown with respect to time after HSCT. The boxes refer to 25th and 75th percentile; the whiskers, 10th and 90th percentile; and the dots, values outside the 10th and 90th percentile.

Graphic Jump Location



Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 4

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Related Multimedia
Articles Related By Topic
Related Collections
PubMed Articles